Antiandrogens in Prostate Cancer A Key to Tailored Endocrine Tre
The introduction of maximal androgen blockade as a clinical therapy by Brachi and Labrie more than a decade ago led to a huge controversy on the clinical use of antiandrogens in the treatment of prostate cancer. Three consensus meetings were subsequently
- PDF / 18,884,352 Bytes
- 121 Pages / 595.28 x 790.87 pts Page_size
- 27 Downloads / 145 Views
The European School of Oncology gratefully acknowledges sponsorship for the Task Force received from ZENECA Pharmaceuticals
Springer Berlin Heidelberg New York Barcelona Budapest Hong Kong London Milan Paris Santa Clara Singapore Tokyo
L. Denis (Ed.)
Antiandrogens in Prostate Cancer A Key to Tailored Endocrine Treatment
With 54 Figures and 39 Tables
Springer
Professor Dr. Louis Denis Vrije Universiteit Brussel Oncologisch Centrum Antwerpen Algemeen Ziekenhuis Middelheim Lindendreef 1 2020 Antwerp, Belgium
ISBN-13: 978-3-642-45747-0 001: 10.1007/978-3-642-45745-6
e-ISBN-13: 978-3-642-45745-6
Library of Congress Cataloging-in-Publication Data Antiandrogens in prostate cancer 1 L. Denis, (ed.). (ESO monographs) Includes bibliographical references. ISBN 978-3-642-45747-0 1. Prostate--Cancer--Chemotherapy. 2. Antiandrogens--Therapeutic use. I. Denis, L. II. Series: Monographs (European School of Oncology) RC280.P7A58 1996 616.99'463--dc20 This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer-Verlag. Violations are liable for prosecution under the German Copyright Law. © Springer-Verlag Berlin Heidelberg 1996
Softcover reprint of the hardcover 15t edition 1996
The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for gerneral use. Product liability: The publishers cannot guarantee the accuracy of any information about dosage and application contained in this book. In every individual case the user must check such information by consulting the relevant literature. Typesetting: Camera ready by editor Printed on acid-free paper
Foreword
The European School of Oncology came into existence to respond to a need for information, education and training in the field of the diagnosis and treatment of cancer. There are two main reasons :o/hy such an initiative was considered necessary. Firstly, the teaching of oncology requires a rigorously multidisciplinary approach which is difficult for the Universities to put into practice since their system is mainly disciplinary orientated. Secondly, the rate of technological development that impinges on the diagnosis and treatment of cancer has been so rapid that it is not an easy task for medical faculties to adapt their curricula flexibly. With its residential courses for organ pathologies and the seminars on new techniques (laser, monoclonal antibodies, imaging techniques etc.) or on the principal therapeutic controversies (co
Data Loading...
